Protagenic therapeutics' innovative peptide pt00114 to be highlighted at boston summit

Chief operating officer to present key advances at peptide therapeutics summit new york, ny / accesswire / april 17, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a pioneer in biopharmaceutical research, announced today that dr. andrew slee, chief operating officer, will present a talk on pt00114, the company's promising new drug candidate, at the peptide based therapeutic summit in boston. titled "novel blood-brain barrier penetrating peptide: opening new doors in neuro-psychiatric treatment," dr. slee's talk will focus on the groundbreaking structure of pt00114, designed to efficiently cross the blood-brain barrier and unlock new potential in treating serious neuro-psychiatric conditions.
PTIX Ratings Summary
PTIX Quant Ranking